Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals share news and announcements
637 announcements, routine notices left out, newest first. Page 11 of 13.
Feb 2014
Jan 2014
2 Jan · Updates
Trading window for dealing with securities of the Company will be closed for the employees & Directors w.e.f. January 01, 2014 till the date of Board Meeting (both days inclusive) proposed to be held for consideration of unaudited financial results for quarter ending December 31, 2013; and it will reopen after 24 hours of the publication of the aforesaid financial results.
Nov 2013
26 Nov · News Verification
News Verification : The media had reports that " US based generic drug maker Mylan and two Indian Pharma Cos are in race to accquire Bafna Pharmaceuticals Ltd" . The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Bafna Pharmaceuticals Limited has vide its letter inter-alia stated, "We wish to clarify that the news report appearing in the section of media regarding Bafna Pharma are speculative. The Company has a policy of desisting to comment on any speculations. Yet in the larger interest of stakeholders and others concerned, we wish to inform you that the Company has been looking for raising money from various modes. In the normal course of business some negotiations are taking place which are at primitive stage."26 Nov · Clarifies on news item
With reference to the news item appearing in a leading financial daily titled "Mylan, 2 Indian Cos Eye Bafna Pharma", Bafna Pharmaceuticals Ltd has clarified to BSE as under: "The ....20 Nov · Business
After successful of launch of RARICAP in oral dosage forms in Domestic Market. The Company has launched RARICAP in injection form ....8 Nov · Board meeting
Among the others to consider : (i) The Un-Audited Financial Results for the Quarter ending September 30, 2013.
Oct 2013
3 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2013
12 Sep · Dividend
Proposed dividend, if approved at the ensuing Annual General Meeting will be distributed on or around October 5, 2013.
Aug 2013
14 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 10, 2013 has transacted the following: (1) Appointment of Mr. Kamlesh Kumar as Additional Director (Non-Executive Independent Director). And further Mr. Kamlesh Kumar was made as a member of Audit Committee. (2) Cancelled 25,00,000 convertible Warrants allotted on January 13, 2012 for nonpayment of balance money within 18 months and forfeited the 25% (application) money paid at the time of allotment of warrants. (3) Proposed the appointment of Mr. Kamlesh Kumar, Independent Director on the Board of Subsidiary M/s. Bafna Lifestyles Remedies Limited.13 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 10, 2013, inter alia, has transacted the following: 1. Appointment ....2 Aug · Board meeting
Inter alia, to consider the following: 1. The Un-Audited Financial Results for the Quarter ending June 30, 2013. 2. To consider appointment of Additional Director. 3. To consider appointment of a Director in the Board of Subsidiary M/s. Bafna Lifestyles Remedies Limited. 4. To consider cancellation of 25,00,000 warrants for non-payment of balance money within the stipulated period.2 Aug · Board Meeting on August 10, 2013
Meeting of the Board of Directors of the Company will be held on August 10, 2013, inter alia, to consider the following: 1. The ....
Jul 2013
29 Jul · Updates
This is being addressed to all our valued investors and others concerned with the company with regard to continued selling of our ....25 Jul · Updates
Company has received Merit Award for the year 2012 from the State Pharmaceuticals Corporation of Sri Lanka during the 16th SPC Suppliers Convention 2013.25 Jul · Business
Company has received Merit Award for the year 2012 from the State Pharmaceuticals Corporation of Sri Lanka during the 16th SPC Suppliers’ ....24 Jul · Updates
Company's facility at Grantlyon has been approved by Ministry of Health and Social Welfare, Tanzania Food and Drugs Authority, The United Republic of Tanzania. With the help of this approval the Company can export to Tanzania.24 Jul · Approval for facility at Grantlyon from Tanzania
Facility at Grantlyon has been approved by Ministry of Health and Social Welfare, Tanzania Food and Drugs Authority, The United Republic ....5 Jul · Meeting
Register of Members & Share Transfer Books of the Company will remain closed from September 21, 2013 to September 30, 2013 (both days ....5 Jul · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from September 21, 2013 to September 30, 2013 (Both Days inclusive) for the purpose of payment of dividend and Annual General Meeting of the Company to be held on September 30, 2013.
May 2013
22 May · Board meeting
Board of Directors of the Company at its meeting held on May 22, 2013, have: (1) Accepted the resignation of Mr. A. Sahasranaman, Independent Director with immediate effect, who has resigned due to personal commitments. Board placed on record their appreciation for the contribution made & valuable advices provided by him during him tenure. (2) Re-appointed Statutory Auditor subject to approval of shareholders in the forthcoming Annual General Meeting.22 May · Board meeting
Board of Directors of the Company at its meeting held on May 20, 2013, has transacted the following; 1. Accepted the resignation ....21 May · Dividend
Board of Directors of the Company at its meeting held on May 20, 2013, inter alia, has transacted the following : 1. Have recommended ....21 May · Management
Board of Directors of the Company at its meeting held on May 20, 2013 has approved the re-appointment of Mr. Bafna Mahaveer Chand as Chairman & Managing Director and Mr. Paras Bafna as Whole Time Director.21 May · Dividend
Board of Directors of the Company at its meeting held on May 20, 2013 has recommended a final dividend of Rs. 0.60 per equity share (6%), subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.15 May · Board meeting
Inter alia;(1) To consider and approve Audited Financial Results of the Company for the year ended March 31, 2013 on Standalone and Consolidated basis.(2) To recommend payment of dividend, if any.(3) To consider re-appointment of Mr. Bafna Mahaveer Chand as Chairman and Managing Director.(4) To consider re-appointment of Mr. Paras Bafna as Whole Time Director.15 May · Board meeting
Meeting of the Board of Directors of the Company will be held on May 20, 2013, inter alia; 1. To consider and approve Audited Financial ....10 May · Bafna Pharmaceuticals double the sales of Raricap
3 May · Bafna Pharmaceuticals receives product approval for Ghana
2 May · Management
Vide letter dated May 02, 2013 that the Company has appointed M/s Minepro Communications for marketing serviecs. The Company had entered into agreement with M/s. Minepro Communications for marketing services which include advertising and publicity. The Company further confirms that : 1. The above Company for any of their associates have any shareholding in the Company. 2. None of the person from the above media companies appointed any nominee Director on the Board of the Company; or, 3. There is no management control or any potential conflict of interest arising out of these agreements. 4. Except as provided hereinabove, the Company has not entered into any other back to back treaties / contracts / agreements / MoUs or similar instruments with media companies and / or their associates for the purpose of advertising publicity etc.2 May · Management
Company had entered into agreement with M/s. Minepro Communications for marketing services which include advertising and publicity. The ....
Apr 2013
27 Apr · Results
Company will publish its Audited Annual Accounts for the financial year ending March 31, 2013 on or before May 30, 2013, hence will not ....